I randomiserede kliniske studier hos patienter med malignitet, der fik Neupopeg efter cytotoksisk kemoterapi, var de fleste uønskede hændelser forårsaget af den underliggende malignitet eller cytotoksisk kemoterapi.
In randomised clinical studies in patients with malignancy receiving Neupopeg after cytotoxic chemotherapy, most adverse events were caused by the underlying malignancy or cytotoxic chemotherapy.